“..when we learned about the Cancer Guardian program, we were immediately compelled to offer this comprehensive support to our family of employees to assure that they have the support and guidance if needed. Cancer Guardian is a truly unique employee benefit.” – Scott Perry, CEO, AmeriLife
“…providing the Cancer Guardian benefit allowed us to align our mission to our benefits, and deliver an extraordinary service to our teammates and their families. It is an offering that will provide benefits that extend beyond what we can forsee.” – Juanita Simpson, Dr. HR & Corporate Training, Administrative Services Organization
“…I strongly recommend Cancer Guardian to other employers who are looking to stay competitive in the talent market and round out their employee benefits program.” – Greg Nicket, VP, Human Resources, Conning & Company
“…Penn Mutual’s greatest strength is its people. Cancer can impact anyone, and the Cancer Guardian program further strengthens our commitment to our associates at times when they need it the most.” – David O’Malley, President & COO, The Penn Mutual Life Insurance Company
By 2030, cancer is expected to surpass heart disease the #1 cause of death in the U.S.(11) Cancer is the leading driver of healthcare costs and has an extensive impact on productivity and presenteeism within the workforce.
As an employer, you need an innovative cancer strategy like Cancer Guardian that provides the resources to your employees when they need it most.
Challenges for Employers
Cancer is costly
Cancer is the #1 high-cost insurance claim for self-insured employers(12)
References
1.Lifetime Risk of Developing or Dying from Cancer Basic Facts. American Cancer Society, 2019.
2.Wamberg Genomic Advisors, Cancer Survey of 204 cancer patients and nonprofessional advocates. Survey Sampling International (SSI), 2018.
3.Unger, Joseph M., et al. Systematic Review and Meta-Analysis of the Magnitude of Structural, Clinical and Physician and Patient Barriers to Cancer Clinical Trial Participation. JNCI J NATL Cancer Institute, 2019.
4.Family Reach. Annual Report 2016. Family Reach Foundation https://familyreachorg/wp-content/uploads/2017/05/ frf_2016_annual_report_compressedpdf Accessed July 30, 2017.
5.CancerCare. Cancer Care Patient Access and Engagement Report. New York: CancerCare. 2016.
6.Manchanda, Ranjit, et al. Population based germline testing for primary cancer prevention. Oncotarget, 2018, Vol. 9 (No. 69), pp: 33062-33063
7.Waszak, Przemyslaw M. et al. The Spread of Medical Fake News in Social Media. Health Policy & Technology Review, Elsevier, 2018.
8.Stephen S. Raab, Dana M. Grzybicki, CA Cancer J. Clin. 2010 May-Jun,60(3): 139-65
9.Raab, Stephen S. MD, et al. Quality in Cancer Diagnosis. Cancer J. Clinical 2010
10.J. Unger, et al., Systematic Review and Meta-Analysis of the Magnitude of Structural, Clinical and Physician Barriers to Cancer Clinical Trial Participation, JNCI J Natl Cancer Inst 2019
11.The State of Cancer Care in America, 2014: A report by the American Society of Clinical Oncology. Journal of Oncology Practice, 2014; 10(2):120-122
12.Sun Life Stop-Loss Report, 2019. https://sunlife.showpad.com/share/7SzmNmJJs1a6msorM0DZA
14.Measuring Health-Related Productivity Loss. https://ww.liebertpubl.com/doi/pdf/10.3322/caac.20068.
16. Wamberg Genomic Advisors Cancer Survey of 204 cancer patients and nonprofessional advocates fielded by Survey Sampling International (SSI), 2018. Available at: https://www.managedhealthcareexecutive.com/leukemia-and-lymphoma/most-troubling-part-cancer-treatment-patients
Knowing how to help
Over 1/3 of all cancer survivors are working age and managers need to have appropriate training and skill to support their direct-reports who have cancer(13)
Having the right resources
Employers need to provide dedicated cancer resources for their employees to promote better care and efficient spend.
Challenges for Employees
Cancer is confusing
A cancer diagnosis for an employee or their family can be devastating, lonely, and confusing
Finding accurate information
Employees dealing with cancer spend 9 hours per month on average (often during work) researching cancer cures and other cancer related topics.(14)
Personalized treatment
The standard of care is typically a one size fits all approach. Access to advanced DNA testing and cancer care advocacy are not typically covered by insurance.
Give your employees potentially
life saving support.
1. Lifetime Risk of Developing or Dying from Cancer Basic Facts. American Cancer Society, 2019.
2. Wamberg Genomic Advisors, Cancer Survey of 204 cancer patients and nonprofessional advocates. Survey Sampling International (SSI), 2018.
3. Unger, Joseph M., et al. Systematic Review and Meta-Analysis of the Magnitude of Structural, Clinical and Physician and Patient Barriers to Cancer Clinical Trial Participation. JNCI J NATL Cancer Institute, 2019.
4. Family Reach. Annual Report 2016. Family Reach Foundation https://familyreachorg/wp-content/uploads/
2017/05/ frf_2016_annual_report_compressedpdf Accessed July 30, 2017.
5. CancerCare. Cancer Care Patient Access and Engagement Report. New York: CancerCare. 2016.
6. Manchanda, Ranjit, et al. Population based germline testing for primary cancer prevention. Oncotarget, 2018, Vol. 9 (No. 69), pp: 33062-33063
7. Waszak, Przemyslaw M. et al. The Spread of Medical Fake News in Social Media. Health Policy & Technology Review, Elsevier, 2018.
8. Stephen S. Raab, Dana M. Grzybicki, CA Cancer J. Clin. 2010 May-Jun,60(3): 139-65
9. Raab, Stephen S. MD, et al. Quality in Cancer Diagnosis. Cancer J. Clinical 2010
10. J. Unger, et al., Systematic Review and Meta-Analysis of the Magnitude of Structural, Clinical and Physician Barriers to Cancer Clinical Trial Participation, JNCI J Natl Cancer Inst 2019
11. The State of Cancer Care in America, 2014: A report by the American Society of Clinical Oncology. Journal of Oncology Practice, 2014; 10(2):120-122
12. Sun Life Stop-Loss Report, 2019. https://sunlife.showpad.com/share/
7SzmNmJJs1a6msorM0DZA
14. Measuring Health-Related Productivity Loss. https://ww.liebertpubl.com/doi/pdf/10.3322/caac.20068.
16. Wamberg Genomic Advisors Cancer Survey of 204 cancer patients and nonprofessional advocates fielded by Survey Sampling International (SSI), 2018. Available at: https://www.managedhealthcareexecutive.com/leukemia-and-lymphoma/
most-troubling-part-cancer-treatment-patients
